P269 DESCRIBING ADHERENCE DATA IN A CLINICAL EFFECTIVENESS TRIAL: THE SALFORD LUNG STUDY IN COPD (SLS COPD)

10.1136/thoraxjnl-2017-210983.468

S Collier: Employment and stock ownership (GSK)
D Browning: Employment and stock ownership (GSK)
JP New: During the SLS COPD study, JPN received research funding towards post via NorthWest EHealth, Salford, UK
JM Gibson: Employing organisation provided IT support for automated data capture collected during SLS COPD
L Stephens: Employment and stock ownership (GSK)
N Diar Bakerly: NDB employing organisation provided IT support to automated data collection method for the SLS COPD trial. NDB received financial support to attend meetings in the form of non-restricting educational grants from GSK, Novartis, AZ, and BI.
J Fletcher: Employment and stock ownership (GSK)
J Crawford: Employment and stock ownership (GSK)

P270 IDENTIFICATION OF RESPONDER GROUPS TO FLUTICASONE FUROATE/VILANTEROL (FF/VI) IN THE SALFORD LUNG STUDY IN COPD (SLS COPD) USING A CLUSTER ANALYSIS MODEL

10.1136/thoraxjnl-2017-210983.469

A Nicholls: Employment and stock ownership (GSK)
N Diar Bakerly: Employing organisation provided IT support to automated data collection method for the SLS COPD trial. NDB received financial support to attend meeting in the form of non-restricting educational grants from GSK, Novartis, Astra Zeneca and BI
S Collier: Employment and stock ownership (GSK)
H Dickinson: Employment and stock ownership (GSK)
D Leather: Employment and stock ownership (GSK)
I Boucot: Employment and stock ownership (GSK)

P271 EFFECT OF EXTRAFINE SINGLE INHALER TRIPLE THERAPY ON LUNG FUNCTION AND USE OF RESCUE MEDICATION: RESULTS FROM THE TRINITY STUDY

10.1136/thoraxjnl-2017-210983.470

The research was funded by Chiesi Farmaceutici S.p.A.
M Scuri, I Montagna, C Francisco, G Cohuet, S Vezzoli, A Muraro and S Petruzzelli are employees of Chiesi Farmaceutici S.p.A.
J Vestbo has received honoraria from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK and Novartis.
D Singh has received honoraria from Apellis, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Johnson and Johnson, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Skypharma, Teva, Therevance and Verona.
M Corradi has received honoraria from Chiesi.
A Papi reports grants, personal fees, and/or reimbursement of travel expenses from Astrazeneca, Chiesi, Boehringer

Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Mundipharma, Novartis, Teva, Sanofi, Zambon.

P272 IMPROVEMENTS IN EXACERBATION RATES WITH SINGLE INHALER TRIPLE THERAPY VERSUS DUAL ICS/LABA THERAPY IN PATIENTS WITH ADVANCED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): SUBGROUP ANALYSES OF THE PHASE III FULFIL STUDY

10.1136/thoraxjnl-2017-210983.471

E Hilton employee of GSK and holds stock options/shares
N Brearley employee of GSK and holds stock options/shares
R Birk employee of GSK and holds stock options/shares
C-Q Zhu employee of GSK and holds stock options/shares
GJ Criner received grants from US NIH and the Department of Defense, consulting from AstraZeneca, Boehringer Ingelheim, Holaira, Mereo, Third Pole, PneumRX, Pulmonx, Pearl, Amirall, CSA Medical, Broncus, AVISA, Lungpacer and GlaxoSmithKline; and contracted clinical trials from AstraZeneca, Avisa, Mereo,Boehringer Ingelheim, Broncus, GlaxoSmithKline, Lungpacer,Novartis, Pulmonx, PneumRx/BTG, and Yungjin
M Dransfield received grants from US NIH and the Department of Defense, consulting from AstraZeneca, Boehringer Ingelheim, Boston Scientific, Genentech, and GlaxoSmithKline; and contracted clinical trials from AstraZeneca, Boehringer Ingelheim, Boston Scientific, GlaxoSmithKline, Novartis, Pulmonx, PneumRx/BTG, and Yungjin
D Halpin received personal fees from GSK; personal fees and non-financial support from AstraZeneca; personal fees and non-financial support from Boehringer Ingelheim; personal fees and non-financial support from Novartis; personal fees from Pfizer; personal fees from Chiesi
DA Lomas received grants, honoraria, and consultancy fees from GSK and chaired the GSK Respiratory Therapy Area Board from 2012–2015
DA Lipson employee of GSK and holds stock options/shares

P273 ASSOCIATION OF INCIDENT PNEUMONIA AND EXACERBATIONS WITH EXTRAFINE TRIPLE THERAPY IN ONE SINGLE INHALER IN COPD PATIENTS: A POST-HOC ANALYSIS FROM TRILOGY AND TRINITY STUDIES

10.1136/thoraxjnl-2017-210983.472

The research was funded by Chiesi Farmaceutici S.p.A.
M Scuri, M Spinola, I Montagna, C Francisco, G Cohuet, S Vezzoli, A Muraro and S Petruzzelli are employees of Chiesi Farmaceutici S.p.A.
J Vestbo has received honoraria from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK and Novartis.
D Singh has received honoraria from Apellis, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Johnson and Johnson, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Skypharma, Teva, Therevance and Verona.
M Corradi has received honoraria from Chiesi.

A Papi reports grants, personal fees, and/or reimbursement of travel expenses from Astrazeneca, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Mundipharma, Novartis, Teva, Sanofi, Zambon.

P275 **COMPARING CLINICALLY RELEVANT IMPROVEMENT WITH UMECLIDINIUM/VILANTEROL AND TIOTROPIUM/ OLODATEROL IN SYMPTOMATIC COPD: A RANDOMISED NON-INFERIORITY CROSSOVER TRIAL**

10.1136/thoraxjnl-2017-210983.473

This study (204990 [NCT02799784]) was funded by GSK.

C Compton, AR Sousa, D Lipson, I Naya and S Patel are employees of GSK and hold stocks/shares in GSK.

L Tombs is a contingent worker on assignment at GSK.

G Feldman has no disclosures to declare.

B Alcázar Navarrete declares the following conflicts of interest: personal fees and non-financial support from Boehringer Ingelheim, Chiesi and GSK; grants, personal fees and non-financial support from Novartis AG and Laboratorios Menarini; and personal fees from Astra-Zeneca and Gebro. In addition, Dr. Alcázar Navarrete has a patent (P201730724) pending.

P276 **CARDIOVASCULAR SAFETY OF EXTRAFINE SINGLE INHALER TRIPLE COMBINATION OF BECLOMETASONE DIPROPIONATE, FORMOTEROL FUMARATE, AND GLYCOPYRRONIUM BROMIDE IN COPD: RESULTS OF SAFETY ANALYSIS FROM THE TRILOGY AND TRINITY STUDIES**

10.1136/thoraxjnl-2017-210983.474

The research was funded by Chiesi Farmaceutici S.p.A.

M Scuri, I Montagna, C Francisco, G Cohuet, S Vezzoli, A Muraro and S Petruzzelli are employees of Chiesi Farmaceutici S.p.A.

J Vestbo has received honoraria from AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK and Novartis.

D Singh has received honoraria from Apellis, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Genentech, GlaxoSmithKline, Glenmark, Johnson and Johnson, Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer, Pulmatrix, Skypharma, Teva, Therevance and Verona.

M Corradi has received honoraria from Chiesi.

A Papi reports grants, personal fees, and/or reimbursement of travel expenses from Astrazeneca, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Mundipharma, Novartis, Teva, Sanofi, Zambon.

M29 **FVC DECLINE OVER 1 YEAR PREDICTS MORTALITY BUT NOT SUBSEQUENT FVC DECLINE IN PATIENTS WITH IPF**

10.1136/thoraxjnl-2017-210983.475

L Richeldi reports grants and personal fees from Boehringer Ingelheim, during the conduct of the study; grants and personal fees from InterMune, personal fees from Medimmune, personal fees from Biogen-Idec, personal fees from Sanofi-Aventis, personal fees from Roche, personal fees from Takeda, personal fees from ImmuneWorks, personal fees from Shionogi, outside the submitted work.

M Kolb reports grants and personal fees from Boehringer Ingelheim, during the conduct of the study; grants and personal fees from Roche, grants and personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from Gilead, grants from Actelion, grants from Respivert, personal fees from Astra Zeneca, personal fees from Prometic, personal fees from Genoa, grants from Canadian Institute for Health Research, grants from Canadian Pulmonary Fibrosis Foundation, outside the submitted work.

A Azuma reports personal fees from Boehringer Ingelheim, outside the submitted work.

W Stansen, M Quaresma and S Stowasser are employees of Boehringer Ingelheim.

B Crestani reports personal fees and non-financial support from astra-zeneca, grants, personal fees and non-financial support from boehringer ingelheim, non-financial support from cardif, non-financial support from lvi, personal fees and non-financial support from apellis, grants from medImmune, personal fees and non-financial support from sanofi, outside the submitted work.

M30 **EFFECT OF DOSE REDUCTIONS AND/OR INTERRUPTIONS ON THE EFFICACY OF NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): SUBGROUP ANALYSIS OF THE INPULSIS TRIALS**

10.1136/thoraxjnl-2017-210983.476

T Maher reports that he is an investigator in an ongoing phase 2b study from Gilead, grants and personal fees from GSK, grants from Novartis, personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from InterMune, personal fees from Lanthio, non-financial support from Takeda, personal fees from Sanofi Aventis, grants and non-financial support from UCB, personal fees from Astra Zeneca, personal fees from Roche, personal fees from Bayer, personal fees from Biogen Idec, personal fees from Cipla, personal fees from DOSA, personal fees from ProMetic, personal fees from Galapagos, outside the submitted work.

Y Inoue personal fees from Boehringer Ingelheim, personal fees from Shionogi & Co., Ltd, personal fees from Asahi Kasei, personal fees from Novartis, personal fees from Nobel Pharma, outside the submitted work.

AH Case reports personal fees from Boehringer Ingelheim, outside the submitted work.